On March 5, 2024 PhotonPharma, a biotechnology company dedicated to revolutionizing cancer treatment, reported that it has received clearance from the U.S. Food and Drug Administration (FDA) to proceed with its Phase I clinical study for the treatment of Stage III/IV ovarian cancer using Innocell, its investigational groundbreaking autologous cell-based vaccine therapy (Press release, PhotonPharma, MAR 5, 2024, View Source;receives-fda-clearance-for-a-first-in-human-clinical-study-for-stage-iiiiv-ovarian-cancer-treatment-with-the-investigational-autologous-vaccine-therapy-innocell-302079350.html [SID1234640820]). This therapeutic approach employs inactivated tumor cells, prepared by a proprietary process based on UV light and riboflavin, after isolation of the cells from a patient’s tumor. These inactivated cells are used in a treatment designed to recruit the patient’s own immune system to fight the cancer. The vaccine therapy will be manufactured at City of Hope’s Los Angeles campus in its Biological and Cellular GMP Manufacturing Facility.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
This milestone achievement underscores PhotonPharma’s commitment to advancing innovative therapies that have the potential to transform the lives of patients battling aggressive forms of cancer.
PhotonPharma CEO, Alan Rudolph, expressed his enthusiasm, stating, "We are thrilled to have reached this pivotal moment in our journey toward providing a novel treatment option for patients facing advanced ovarian cancer. This milestone speaks to the dedication and expertise of our team, as well as the potential of Innocell to make a meaningful impact in oncology."
Ray Goodrich, CSO and co-founder of PhotonPharma, added, "The FDA’s clearance to proceed into our clinical study with Innocell marks a significant step in developing this new therapy. We remain committed to advancing an innovative therapy that may address unmet needs in cancer treatment."
Taby Ahsan, Ph.D., Vice President of Cell and Gene Therapy Operations at City of Hope in Los Angeles, said, "We are excited to collaborate with PhotonPharma in advancing Innocell towards clinical development. We look forward to contributing our decades of experience in cell- and gene-based therapies to the progress of this important program."
The Phase 1 clinical trial for Innocell will evaluate its safety, tolerability, and potential immune response indicators in patients with Stage III/IV ovarian cancer. PhotonPharma anticipates initiating patient enrollment in the near future, with the aim of profiling the therapeutic potential of this innovative autologous vaccine therapy.